Thermo Fisher Sells Microbiology Business to Astorg for $1.08B
Thermo Fisher Scientific is divesting its microbiology business to Astorg for $1.075 billion, impacting lab operations. This sale highlights a trend of larger companies offloading specialized units, compelling lab managers to reassess supplier strategies and prepare for operational disruptions.
Theia Market Signal Identification - AI Assisted
Thermo Fisher Scientific has finalized an agreement to sell its microbiology business to Astorg for approximately $1.075 billion, expecting to close in H2 2026. The microbiology unit generated $645 million in revenue in 2025 and includes critical antimicrobial susceptibility testing (AST) products and culture media essential for quality control in various lab settings.
Lab managers should proactively review inventory strategies and assess vendor dependencies, anticipating changes in delivery schedules and pricing post-acquisition. This divestiture is part of Thermo Fisher's strategy to concentrate on higher-growth areas such as biopharma services and laboratory automation. The transition underscores the necessity for robust supplier qualification frameworks as regulatory oversight intensifies, ensuring compliance and operational continuity.
Comments